Bavisant dihydrochloride is under clinical development by BenevolentAI and currently in Phase II for Hypersomnia. According to GlobalData, Phase II drugs for Hypersomnia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bavisant dihydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bavisant dihydrochloride overview
Bavisant dihydrochloride (BEN-2001, JNJ-31001074) is under development for the treatment of excessive daytime sleepiness (EDS) in patients with Parkinson's disease. The drug candidate is administered orally as a tablet. It targets H3 receptor and is developed using artificial intelligence technology. It was also under development for the treatment of attention-deficit/hyperactivity disorder (ADHD) and alcohol dependence.
See Also:
BenevolentAI overview
BenevolentAI is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s drug programs include BEN2293 (atopic dermatitis), BEN8744 (ulcerative colitis), BEN9160 (amyotrophic lateral sclerosis), glioblastoma multiforme, inflammatory bowel disease, CNS diseases, antiviral, nonalcoholic steatohepatitis (NASH), oncology, Parkinson’s disease, chronic kidney disease, idiopathic pulmonary fibrosis and others. BenevolentAI’s platform enables scientists to design and develop new treatments for patients, using a large amount of extracted and deduced biomedical information. The company operates in the UK and the US. BenevolentAI is headquartered in London, England, the UK.
For a complete picture of Bavisant dihydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
